Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.
Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts. Clin Cancer Res. 2015 Dec 15; 21(24):5588-600.
View in:
PubMed
subject areas
Animals
Animals
Antineoplastic Agents
Antineoplastic Agents
Apoptosis
Apoptosis
Breast Neoplasms
Breast Neoplasms
Cell Line, Tumor
Cell Line, Tumor
Disease Models, Animal
Disease Models, Animal
Female
Female
Gene Expression Regulation, Neoplastic
Gene Expression Regulation, Neoplastic
Humans
Humans
Mice
Mice
Mutation
Mutation
Phosphatidylinositol 3-Kinases
Phosphatidylinositol 3-Kinases
Protein Kinase Inhibitors
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-met
Proto-Oncogene Proteins c-met
Receptor Protein-Tyrosine Kinases
Receptor Protein-Tyrosine Kinases
Receptors, Estrogen
Receptors, Estrogen
Receptors, Progesterone
Receptors, Progesterone
Signal Transduction
Signal Transduction
Tumor Burden
Tumor Burden
Xenograft Model Antitumor Assays
Xenograft Model Antitumor Assays
authors with profiles
Magdalena Bieniasz